Primary Biliary Cholangitis
Zydus Therapeutics Inc. is active in hepatology through clinical research focused on Primary Biliary Cholangitis, a chronic autoimmune liver disease affecting bile duct function and liver biochemistry.
- Cholestatic liver disease
- Bile duct inflammation
- Alkaline phosphatase
- Total bilirubin
The sponsor’s work in this area centers on biochemical response and liver-related disease control within autoimmune liver disorders.
Amyotrophic Lateral Sclerosis
The company also supports research in neurology, with a therapeutic focus on Amyotrophic Lateral Sclerosis, a progressive motor neuron disease associated with loss of muscle function and declining mobility.
- Neuromuscular function
- Functional decline
- Survival outcomes
- ALSFRS-R
Its clinical activity reflects interest in disease progression, functional assessment, and outcomes relevant to neurodegenerative disorders.
Inflammatory and Metabolic Pathways
Zydus Therapeutics Inc. is engaged in therapeutic areas connected to inflammation, metabolic regulation, and lipid-related biology, as reflected in its studies across liver and neuromuscular disease settings.
- Inflammatory signaling
- Metabolic modulation
- Liver biochemistry
- Systemic disease mechanisms
These areas indicate a research emphasis on conditions where immune, metabolic, and tissue-specific pathways contribute to clinical burden.
Multinational Clinical Development
The sponsor’s clinical research spans multiple countries and collaborating sites, supporting studies in both rare disease and specialty therapeutic settings.
- International trial sites
- Rare disease research
- Specialty medicine
- Cross-border enrollment
This footprint is aligned with therapeutic development in diseases requiring specialized clinical expertise and coordinated patient access.
